Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Adverse events including extrapyramidal effects · terminally ill adults with delirium
It is very uncertain whether summary of findings: haloperidol changes adverse events including extrapyramidal effectsc compared with lorazepam (very low certainty).
1 finding from 1 review
Adverse events including extrapyramidal effects · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in adverse events including extrapyramidal effectse compared with placebo (moderate certainty).
1 finding from 1 review
Symptoms of delirium within 24 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium within 24 hoursa compared with risperidone (low certainty).
1 finding from 1 review
Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium
Summary of findings: haloperidol showed no clear difference in symptoms of delirium between 24 and 48 hoursa compared with risperidone (low certainty).
1 finding from 1 review
Specific behaviour ‐ agitation · terminally ill adults with delirium
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Change in weight (kg) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Change in height · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in BMI · children aged 7 years or over and adults with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
CFA: change from baseline (%) · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Adverse events · children aged 7 years or over and adults with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · children aged 7 years or over and adults with cystic fibrosis
Summary of findings: liprotamase showed no clear difference in pulmonary exacerbations: number of exacerbations compared with porcine PERT (low certainty).
1 finding from 1 review
Mean change in visual acuity at 1 year (number of letters) · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in mean change in visual acuity at 1 year (number of letters) compared with ranibizumab (high certainty).
1 finding from 1 review
Reduction in central retinal thickness at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in reduction in central retinal thickness at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
No problems in quality of life domains at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in no problems in quality of life domains at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious systemic adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious systemic adverse events at 1 yearb compared with ranibizumab (moderate certainty).
1 finding from 1 review
Serious ocular adverse events at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in serious ocular adverse events at 1 year compared with ranibizumab (moderate certainty).
1 finding from 1 review
RR 0.51 [0.05, 5.62]
1670 participants
Moderate
BCVA: gain of 15 or more ETDRS letters · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in gain of 15 or more letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review
Loss of fewer than 15 letters visual acuity at one year · people with neovascular age‐related macular degeneration
Summary of findings: bevacizumab showed no clear difference in loss of fewer than 15 letters visual acuity at 1 year compared with ranibizumab (high certainty).
1 finding from 1 review